STOCK TITAN

[6-K] Biophytis SA Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K

Biophytis S.A. reported that it issued a press release announcing a partnership with a consortium of investors, including RONGHUI RENHE Life Technology, to finance and launch the first ever Phase-3 trial in sarcopenia. The announcement was furnished on a Form 6-K and the press release is provided as Exhibit 99.1.

Biophytis S.A. ha comunicato di aver emesso un comunicato stampa che annuncia una partnership con un consorzio di investitori, tra cui RONGHUI RENHE Life Technology, per finanziare e avviare la prima triale di fase 3 nella sarcopenia. L’annuncio è stato presentato in un Form 6-K e il comunicato stampa è fornito come Exhibit 99.1.

Biophytis S.A. informó que emitió un comunicado de prensa anunciando una asociación con un consorcio de inversores, incluyendo RONGHUI RENHE Life Technology, para financiar e iniciar la primera prueba de fase 3 en la sarcopenia. El anuncio se presentó en un Form 6-K y el comunicado de prensa se proporciona como Exhibit 99.1.

Biophytis S.A.는 투자자 컨소시엄과의 파트너십을 발표하는 보도자료를 발행했다고 보고했으며, 이 중에는 RONGHUI RENHE Life Technology가 포함되어 있으며, 이 보건 시니의 첫 번째 근감소증에서의 3상 임상시험을 위한 자금 조달 및 출시를 위한 것이라고 밝혔다. 발표는 Form 6-K에 첨부되었고 보도자료는 Exhibit 99.1로 제공된다.

Biophytis S.A. a déclaré avoir publié un communiqué de presse annonçant un partenariat avec un consortium d'investisseurs, comprenant RONGHUI RENHE Life Technology, pour financer et lancer le tout premier essai de phase 3 dans la sarcopénie. L'annonce a été déposée sur un Form 6-K et le communiqué de presse est fourni comme Exhibit 99.1.

Biophytis S.A. berichtete, dass es eine Pressemitteilung veröffentlicht hat, in der eine Partnerschaft mit einem Investorenkonsortium angekündigt wird, darunter RONGHUI RENHE Life Technology, um die erste Phase-3-Studie zur Sarkopenie zu finanzieren und zu starten. Die Ankündigung wurde in einem Form 6-K bereitgestellt und die Pressemitteilung wird als Exhibit 99.1 vorgelegt.

Biophytis S.A. أبلغت عن إصدار بيان صحفي يعلن شراكة مع كونسورتيوم من المستثمرين، بما في ذلك RONGHUI RENHE Life Technology، لتمويل وإطلاق أول تجربة من المرحلة الثالثة في ساركوبينيا. وقد تم تقديم الإعلان في نموذج 6-K، وتم توفير البيان الصحفي كـ Exhibit 99.1.

Biophytis S.A. 报告称其发布了一份新闻稿,宣布与包括 RONGHUI RENHE Life Technology 在内的投资者财团达成合作,为首个 在肌少症中的第三阶段临床试验 提供资助并启动。该公告已在 Form 6-K 上提交,新闻稿作为 Exhibit 99.1 提供。

Positive
  • None.
Negative
  • None.

Biophytis S.A. ha comunicato di aver emesso un comunicato stampa che annuncia una partnership con un consorzio di investitori, tra cui RONGHUI RENHE Life Technology, per finanziare e avviare la prima triale di fase 3 nella sarcopenia. L’annuncio è stato presentato in un Form 6-K e il comunicato stampa è fornito come Exhibit 99.1.

Biophytis S.A. informó que emitió un comunicado de prensa anunciando una asociación con un consorcio de inversores, incluyendo RONGHUI RENHE Life Technology, para financiar e iniciar la primera prueba de fase 3 en la sarcopenia. El anuncio se presentó en un Form 6-K y el comunicado de prensa se proporciona como Exhibit 99.1.

Biophytis S.A.는 투자자 컨소시엄과의 파트너십을 발표하는 보도자료를 발행했다고 보고했으며, 이 중에는 RONGHUI RENHE Life Technology가 포함되어 있으며, 이 보건 시니의 첫 번째 근감소증에서의 3상 임상시험을 위한 자금 조달 및 출시를 위한 것이라고 밝혔다. 발표는 Form 6-K에 첨부되었고 보도자료는 Exhibit 99.1로 제공된다.

Biophytis S.A. a déclaré avoir publié un communiqué de presse annonçant un partenariat avec un consortium d'investisseurs, comprenant RONGHUI RENHE Life Technology, pour financer et lancer le tout premier essai de phase 3 dans la sarcopénie. L'annonce a été déposée sur un Form 6-K et le communiqué de presse est fourni comme Exhibit 99.1.

Biophytis S.A. berichtete, dass es eine Pressemitteilung veröffentlicht hat, in der eine Partnerschaft mit einem Investorenkonsortium angekündigt wird, darunter RONGHUI RENHE Life Technology, um die erste Phase-3-Studie zur Sarkopenie zu finanzieren und zu starten. Die Ankündigung wurde in einem Form 6-K bereitgestellt und die Pressemitteilung wird als Exhibit 99.1 vorgelegt.

 

 

 

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report: October 13, 2025

 

Commission File Number: 001-38974

 

BIOPHYTIS S.A.

(Translation of registrant’s name into English)

 

 

Stanislas Veillet
Biophytis S.A.

Sorbonne University—BC 9, Bâtiment A 4ème étage

4 place Jussieu

75005 Paris, France

+33 1 44 27 23 00

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

x Form 20-F ¨  Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

 

 

 

On October 13, 2025, Biophytis S.A. issued a press release announcing that Biophytis and a consortium of investors including RONGHUI RENHE Life Technology join forces to finance and launch first ever Phase-3 trial in sarcopenia. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.

 

EXHIBIT LIST

 

Exhibit   Description
99.1   Press Release dated October 13, 2025.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BIOPHYTIS S.A.
     
Date: October 13, 2025 By: /s/ Stanislas Veillet
    Name: Stanislas Veillet
    Title: Chairman and Chief Executive Officer

 

 

 

FAQ

What did Biophytis (BPTSY) announce in its Form 6-K?

Biophytis announced partnering with a consortium of investors, including RONGHUI RENHE Life Technology, to finance and launch the first Phase-3 trial in sarcopenia.

Which investors are involved with Biophytis (BPTSY)?

The consortium includes RONGHUI RENHE Life Technology as named in the announcement.

What stage is Biophytis’ sarcopenia program?

The company announced plans to launch the first Phase-3 trial in sarcopenia.

Where can I find the detailed announcement for Biophytis (BPTSY)?

The full press release is attached as Exhibit 99.1 to the Form 6-K.

When was the Biophytis (BPTSY) announcement made?

The announcement is dated October 13, 2025.

What filing type did Biophytis (BPTSY) use for this update?

Biophytis furnished a Form 6-K as a report of a foreign private issuer.
Biophytis Sa

OTC:BPTSY

BPTSY Rankings

BPTSY Latest News

BPTSY Latest SEC Filings

BPTSY Stock Data

5.52M
731.65k
0%
3.22%
Biotechnology
Healthcare
Link
France
Paris